Heterogeneous antinuclear antibodies (ANA) are routinely detected using the indirect immunofluorescent technique, and the identification of distinct patterns of fluorescent staining in substrate nuclei may be a useful means of evaluating the clinical status of patients with systemic lupus erythematosus (SLE). The peripheral pattern of nuclear staining is characteristically associated with the presence of serum antibodies directed against DNA (anti-DNA) (Casals et al., 1963) . In many patients peripheral nuclear staining correlates with active disease (Gonzalez and Rothfield, 1966; Tan, 1967; Rothfield and Stollar, 1967; Luciano and Rothfield, 1973 
with active or quiescent SLE were studied at a single point in the course of their disease. The highest serum titre giving a peripheral pattern (tp-ANA) was considered the end point in positive immunofluorescent ANA tests. Anti-DNA antibodies were measured using a modification of the Farr technique (Walker and Bole, 1975) . Unexpectedly, tp-ANA did not correlate with anti-DNA values or SLE activity. A separate group of 9 patients with lupus flare-ups were followed serially to examine the effects of prednisone therapy on serological parameters of disease activity. In these patients tp-ANA and anti-DNA values fell as disease activity was controlled with medication. Nevertheless, there was no correlation between tp-ANA and anti-DNA values after treatment was started. This study provided evidence that ANA tests with peripheral patterns produced by titred sera do not accurately reflect serum anti-DNA levels or severity of disease in SLE.
Relation of titred peripheral pattern ANA to antr:DNA and disease activity 45 Association criteria for classification of SLE (Cohen et al., 1971) . They were ANA-positive on one or more occasions, during the course of disease, but not necessarily at the time of study.
SLE PATIENTS STUDIED SERIALLY
A separate group of 9 patients was studied because multiple sequential serum samples, including sera with high anti-DNA values, were collected to evaluate disease activity. 8 women and one man, aged 14 to 57 years, were observed for periods of 2 to 7 months. All 9 patients had clinical evidence of renal disease; 8 had biopsy-proven lupus nephritis. Renal biopsy was not performed in one patient. SLE was more active in these 9 patients than in the patients studied at random.
Sera were stored at -70°C. Titred ANA tests and anti-DNA determinations were performed using aliquots of the same serum sample from each patient. Retrospective chart review was used to correlate test results with disease activity.
TITRED ANA The indirect immunofluorescent procedure described by Friou (1967) and adapted by Kay et al. (1971) was used to test thawed sera for heterogeneous ANA on mouse liver substrate. A single lot of fluoresceinconjugated polyvalent antiserum to human gammaglobulin (Grand Island Biological Company, Grand Island, N.Y.) was used. This antiserum was characterized by a molar F/P ratio of 2-5 and protein concentration of 13 mg/ml. The antiserum was diluted 1 :10 before use. Each serum sample was tested after adding phosphate-buffered saline pH 7-2 at dilutions of 1:10, 1:50, 1:100, 1:250, 1:500, and 1:1000. Negative control serum and titred positive control serum were included in each group of tests. The positive control serum was positive consistently with a peripheral pattern in a dilution of 1: 500.
ANTI-DNA Anti-DNA was determined by the modified Farr technique (Walker and Bole, 1975) , using 14C-labelled KB cell DNA. Spectrophotometric, chemical, and enzymatic characterization indicated that greater than 95 % of the radioactive substrate was doublestranded (Walker and Bole, 1975) . In this laboratory binding greater than 20 % reflected raised anti-DNA levels.
RENAL DISEASE
A renal disease index was derived by assigning values of 0-4 to increasingly severe azotaemia and increasing amounts of proteinuria. If cellular casts were found in urine sediment, 2 points were added to the total score (Table) . Renal status was assessed at the time of anti-DNA and ANA testing. In three instances severity of renal disease could not be scored by chart review. The MIDAS software package (Fox and Guire, 1973) was used within the MTS system on the AMDAHL 470V/6 computer to calctulate linear regression, the correlation coefficient r, and r2 (Snedecor and Cochran, 1967) . Mean values derived from groups with unequal numbers of individuals were compared using the t test described by Snedecor and Cochran (1967) . The P value was set at 0-5. (Casals et al., 1963) , the mean anti-DNA value in ANA-positive sera (49 %) was greater than anti-DNA in sera with a negative ANA test (16%). This difference was significant at the 0 0005 level. Unexpectedly, there was no linear correlation between tp-ANA and anti-DNA levels. Fig. 1 shows the relation between titres of sera producing a peripheral ANA pattern and anti-DNA values. Individual samples of serum in dilutions ranging from 1:10 to 1: 500 produced a peripheral pattern on substrate nuclei. In a few instances, when higher dilutions of serum were tested a speckled pattern was observed. Nevertheless, in this study the highest titre of serum producing a peripheral pattern was considered the tp-ANA value. This figure shows that when patients were studied at random there was no linear relation between tp-ANA and anti-DNA (r2=015; P=030). In 12 weakly ANA-positive sera producing a peripheral pattern at a dilution of 1:10, a high mean anti-DNA value of 47% (range 12 %-96 %) was found. In 4 strongly ANA-positive sera with a peripheral pattern at 1: 500 dilution, mean anti-DNA was 50% (range 12 %-95 %). The lack of correlation between tp-ANA and anti-DNA was clear when patients were divided into 2 groups based upon their anti-DNA responses. 14 patients with normal anti-DNA (mean 14%) had median tp-ANA of 1:10. In 34 patients with abnormally high anti-DNA (mean 55 %), median tp-ANA was also 1:10. Fig. 2 shows the relationship between tp-ANA and ARA criteria for the classification of SLE. 36 ANA-positive patients fulfilled a mean number of 3-8 criteria, and 9 patients with negative tests had a mean number of 26 criteria. Although a larger number of criteria were found in patients with positive tests compared to patients with negative tests, tp-ANA did not correlate with the number of criteria present at the time of this study (r2=0 04; P=0 20).
ANTI-DNA AND DISEASE ACTIVITY IN SLE PATIENTS STUDIED AT RANDOM
The relationships between anti-DNA and 3 parameters of disease activity in SLE patients studied at Sequential changes in tp-ANA and anti-DNA in 9 patients with SLE are shown in Fig. 4 . Three to six samples of sera were obtained from each patient. 7 cases were studied serially while flare-ups were treated with prednisone; only the first and last tp-ANA and anti-DNA values are shown in Fig. 4 .
When initial serum samples were tested, high tp-ANA titres were associated with raised anti-DNA values in 6 of these 7 patients. The median tp-ANA was 1:250 and mean anti-DNA was 85%. As treatment continued disease activity decreased. Median tp-ANA fell from 1:250 to 1: 10 and mean anti-DNA 80 2 Months Fig. 4 9 patients with SLE were studied sequentially. 7 with active disease had decreasing tp-ANA and anti-DNA after prednisone therapy was started. 2 patients were followed before, during, and after SLE flare-ups. Tp-ANA and anti-DNA increased when disease became active andfell when the flare-ups were controlled with corticosteroids. Although the test values decreased after treatment, tp-ANA was independent of anti-DNA (r2=002; P=0-30).
48 Weitzman, Walker fell from 81 % to 29%. In 2 instances (Cases 5 and 7) tp-ANA and anti-DNA values were obtained before, during, and after lupus flare-ups. In Cases 5 and 7 tp-ANA and anti-DNA increased when the disease became active. Both values fell when the flare-ups were controlled with prednisone therapy. Fig. 4 suggests that decreasing tp-ANA correlated with decreasing anti-DNA after treatment for SLE was started. Nevertheless, a linear relationship between both parameters was not proven by statistical methods. Calculations using all test results showed that there was no linear relationship between falling tp-ANA and anti-DNA values in treated patients (r2=0 02; P=0 30). The magnitudes of decreases of serological parameters of disease activity were also studied. In each of the 9 patients observed serially, Atp-ANA (tp-ANA in active disease minus tp-ANA after therapy) and A anti-DNA (anti-DNA in active disease minus anti-DNA after therapy) were derived. When Atp-ANA values were plotted against Aanti-DNA values, no linear relationship was seen. Calculation of the regression of Atp-ANA on -Aanti-DNA yielded a r2 value of0 40 (P=0-06).
Discussion
This report describes the first study designed to correlate titres of serum producing the peripheral ANA pattern with serum levels of anti-DNA. In 48 SLE patients studied at one point in the course of their disease tp-ANA was not associated with anti-DNA. Patients whose sera produced the peripheral pattern in high titres could not be separated from patients with low titre peripheral patterns on the basis of severity of renal disease, THC levels, or number of SLE criteria fulfilled. 9 patients with SLE were followed serially. When lupus flare-ups were treated with prednisone, both tp-ANA and anti-DNA decreased. Nevertheless, these values did not correlate with one another. It was concluded that titred ANA tests with a rim pattern were not useful in predicting anti-DNA or assessing SLE activity.
The diversity of antibodies directed against DNA and the nonspecific nature of peripheral nuclear staining may explain the lack of association between tp-ANA and anti-DNA in this study. Anti-DNA comprise a spectrum of antibodies directed against diverse antigenic sites within the DNA molecule (Alarcon-Segovia et al., 1970) . Anti-DNA measured at one point in time may be specific for one or more nuclear antigens, but only certain antibodies may be responsible for the peripheral pattern. Casals et al. (1963) DNA. Barnett et al. (1966) found the peripheral pattern in ANA testing of sera from patients with Felty's syndrome who did not have anti-DNA. Another group of investigators studied 101 patients whose sera produced peripheral staining (Dorsch et al., 1969) . 57 patients had SLE, but 44 patients had other diseases not associated with anti-DNA. Bickel et al. (1968) found peripheral nuclear staining in one-fourth to one-third of ANA tests from patients who had neither lupus nor antibodies to DNA. Tan (1967) reported that the peripheral pattern could be produced by antibodies to soluble nucleoprotein.
This study confirmed the clinical usefulness of anti-DNA determinations. The close correlation between anti-DNA levels and renal disease, decreased THC, and number of SLE criteria in our patients support the observations of others (Pincus et al., 1969 ) that anti-DNA determinations were valuable in monitoring the activity of lupus. In contrast to anti-DNA, titred tests for ANA with peripheral patterns did not correlate with clinical parameters of active SLE. Indirect immunofluorescent testing for ANA is a sensitive method of screening sera for the presence of autoantibodies. Nevertheless, titred ANA tests are of limited value in assessing SLE activity.
